RNA medicines for solid tumors and autoimmune disease
Raised to date
$2.6M
of $2.7M offered across 1 Form D filing
Axelyf is an Icelandic-American biotech developing RNA medicines for oncology and autoimmune disease. Its AXL platform is a lipid nanoparticle delivery system, validated in non-human primates and optimized with ANNA, the company's in-house AI model for lipid design, aimed at delivering RNA beyond the liver. Lead programs are AX-004, an in vivo CAR-T therapy for solid tumors, and AX-003, for autoimmune hepatitis.
Lipid nanoparticles designed with a proprietary AI lipid-design model to deliver RNA to tissues beyond the liver, enabling in vivo CAR-T without ex vivo cell manufacturing.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Oct 13, 2026 | Equity | $2.6M/ $2.7M | Form D |
RNA therapeutic (preclinical)
An in vivo CAR-T program targeting solid tumors, delivered with Axelyf's AXL lipid nanoparticle platform.
Built for
Patients with solid tumors and autoimmune diseases, reached through pharma partners and clinical development
